<p>Heron Therapeutics Inc. 最近召开了财报电话会议，透露出混合的情绪，某些产品线实现了强劲增长并成功融资，但也面临着如 SUSTOL 销售下降和毛利率下降等挑战。尽管因债务清偿报告了净亏损，公司仍在积极的发展轨道上，面临一些财务障碍需要克服。</p>
<h2>成功完成融资</h2>
<p>Heron Therapeutics 成功完成了融资，解决了一个重要的负担。这一成就使管理层能够将重点转向商业执行和产品线的增长，为未来的努力奠定了坚实的基础。</p>
<h2>收入和增长指标</h2>
<p>公司报告本季度总净收入为 3820 万美元，年初至今为 1.143 亿美元。调整后的 EBITDA 本季度为 150 万美元，年初至今为 950 万美元，反映出在市场挑战中稳健的财务表现。</p>
<h2>ZYNRELEF 和 APONVIE 销售增长</h2>
<p>ZYNRELEF 和 APONVIE 的销售增长显著，ZYNRELEF 本季度净销售同比增长 49%，而 APONVIE 在同一时期净销售激增 173%。这一增长凸显了市场对这些产品的强劲需求。</p>
<h2>ZYNRELEF 的永久 J 代码</h2>
<p>预计在 10 月 1 日推出 ZYNRELEF 的永久 J 代码将简化报销流程并支持更广泛的采用，可能会推动未来的销售和市场存在。</p>
<h2>急性护理产品组合的积极趋势</h2>
<p>包括 CrossLink Ignite 和 VAN 在内的新举措导致急性护理产品组合的需求增加。这些举措预计将继续对销售产生积极影响，并增强公司的市场地位。</p>
<h2>SUSTOL 销售下降</h2>
<p>SUSTOL 的净销售同比下降 32%，预计由于市场竞争将继续承受压力。这一下降给公司带来了需要解决的挑战，以稳定其肿瘤学业务。</p>
<h2>毛利率下降</h2>
<p>毛利率从之前的季度下降至 68.8%，主要由于库存准备金和减值的增加。这一下降突显了改善库存管理策略的必要性。</p>
<h2>净亏损</h2>
<p>Heron Therapeutics 报告本季度净亏损 1750 万美元，主要由于 1130 万美元的债务清偿损失。这一财务挫折强调了战略财务规划的重要性。</p>
<h2>前瞻性指导</h2>
<p>展望未来，Heron Therapeutics 重申了其财政年度的指导，预计净收入在 1.53 亿至 1.63 亿美元之间，调整后的 EBITDA 预计在 900 万至 1300 万美元之间。公司对其增长前景保持乐观，得益于战略举措和强劲的产品表现。</p>
<p>总之，Heron Therapeutics 的财报电话会议反映出公司在机遇与挑战中前行。尽管关键产品线的强劲增长和成功融资是积极的指标，但 SUSTOL 销售下降和毛利率下降则是需要改进的领域。总体而言，公司似乎已做好增长的准备，战略举措和前瞻性指导为未来的成功提供了路线图。</p>

HRTX

<p>Heron Therapeutics Inc. 在其财报电话会议中报告了混合的业绩，展示了 ZYNRELEF 和 APONVIE 销售的强劲增长，本季度净收入为 3820 万美元。尽管由于债务清偿导致净亏损 1750 万美元，并且 SUSTOL 销售下降了 32%，但公司成功完成了融资，使其能够专注于商业执行。预计 ZYNRELEF 的永久 J 码将改善报销流程。公司预计本财年的净收入将在 1.53 亿美元至 1.63 亿美元之间，尽管面临当前挑战，但对未来增长持乐观态度</p>

<p>Heron Therapeutics Inc. recently conducted its earnings call, revealing a mixed sentiment with strong growth in certain product lines and successful financing, yet facing challenges such as declining SUSTOL sales and a decrease in gross margin. Despite reporting a net loss due to debt extinguishment, the company is on a positive trajectory with some financial hurdles to overcome.</p>
<div class="lb-trans"><p>Heron Therapeutics Inc. 最近召开了财报电话会议，透露出混合的情绪，某些产品线实现了强劲增长并成功融资，但也面临着如 SUSTOL 销售下降和毛利率下降等挑战。尽管因债务清偿报告了净亏损，公司仍在积极的发展轨道上，面临一些财务障碍需要克服。</p>
</div><h2>Successful Financing Completion</h2>
<div class="lb-trans"><h2>成功完成融资</h2>
</div><p>Heron Therapeutics successfully completed its financing, which has resolved a significant overhang. This achievement allows the management to shift its focus towards commercial execution and the growth of its product lines, setting a solid foundation for future endeavors.</p>
<div class="lb-trans"><p>Heron Therapeutics 成功完成了融资，解决了一个重要的负担。这一成就使管理层能够将重点转向商业执行和产品线的增长，为未来的努力奠定了坚实的基础。</p>
</div><h2>Revenue and Growth Metrics</h2>
<div class="lb-trans"><h2>收入和增长指标</h2>
</div><p>The company reported total net revenues of $38.2 million for the quarter and $114.3 million year-to-date. Adjusted EBITDA was $1.5 million for the quarter and $9.5 million year-to-date, reflecting steady financial performance amidst market challenges.</p>
<div class="lb-trans"><p>公司报告本季度总净收入为 3820 万美元，年初至今为 1.143 亿美元。调整后的 EBITDA 本季度为 150 万美元，年初至今为 950 万美元，反映出在市场挑战中稳健的财务表现。</p>
</div><h2>Growth in ZYNRELEF and APONVIE Sales</h2>
<div class="lb-trans"><h2>ZYNRELEF 和 APONVIE 销售增长</h2>
</div><p>ZYNRELEF and APONVIE have shown impressive sales growth, with ZYNRELEF net sales increasing by 49% year-over-year for Q3, and APONVIE net sales surging by 173% in the same period. This growth underscores the strong market demand for these products.</p>
<div class="lb-trans"><p>ZYNRELEF 和 APONVIE 的销售增长显著，ZYNRELEF 本季度净销售同比增长 49%，而 APONVIE 在同一时期净销售激增 173%。这一增长凸显了市场对这些产品的强劲需求。</p>
</div><h2>Permanent J-Code for ZYNRELEF</h2>
<div class="lb-trans"><h2>ZYNRELEF 的永久 J 代码</h2>
</div><p>The introduction of a permanent J-code for ZYNRELEF on October 1 is anticipated to streamline reimbursement processes and support broader adoption, potentially boosting future sales and market presence.</p>
<div class="lb-trans"><p>预计在 10 月 1 日推出 ZYNRELEF 的永久 J 代码将简化报销流程并支持更广泛的采用，可能会推动未来的销售和市场存在。</p>
</div><h2>Positive Trends in Acute Care Portfolio</h2>
<div class="lb-trans"><h2>急性护理产品组合的积极趋势</h2>
</div><p>New initiatives, including CrossLink Ignite and the VAN, have led to increased demand for the acute care portfolio. These initiatives are expected to continue positively impacting sales and enhancing the company’s market position.</p>
<div class="lb-trans"><p>包括 CrossLink Ignite 和 VAN 在内的新举措导致急性护理产品组合的需求增加。这些举措预计将继续对销售产生积极影响，并增强公司的市场地位。</p>
</div><h2>SUSTOL Sales Decline</h2>
<div class="lb-trans"><h2>SUSTOL 销售下降</h2>
</div><p>SUSTOL net sales decreased by 32% year-over-year, with continued pressure expected due to market competition. This decline presents a challenge that the company needs to address to stabilize its oncology franchise.</p>
<div class="lb-trans"><p>SUSTOL 的净销售同比下降 32%，预计由于市场竞争将继续承受压力。这一下降给公司带来了需要解决的挑战，以稳定其肿瘤学业务。</p>
</div><h2>Gross Margin Decrease</h2>
<div class="lb-trans"><h2>毛利率下降</h2>
</div><p>The gross margin decreased to 68.8% from previous quarters, primarily due to an increase in inventory reserves and write-offs. This decline highlights the need for improved inventory management strategies.</p>
<div class="lb-trans"><p>毛利率从之前的季度下降至 68.8%，主要由于库存准备金和减值的增加。这一下降突显了改善库存管理策略的必要性。</p>
</div><h2>Net Loss</h2>
<div class="lb-trans"><h2>净亏损</h2>
</div><p>Heron Therapeutics reported a net loss of $17.5 million for the quarter, mainly due to an $11.3 million loss on debt extinguishment. This financial setback underscores the importance of strategic financial planning.</p>
<div class="lb-trans"><p>Heron Therapeutics 报告本季度净亏损 1750 万美元，主要由于 1130 万美元的债务清偿损失。这一财务挫折强调了战略财务规划的重要性。</p>
</div><h2>Forward-Looking Guidance</h2>
<div class="lb-trans"><h2>前瞻性指导</h2>
</div><p>Looking ahead, Heron Therapeutics reaffirmed its guidance for the fiscal year, projecting net revenue between $153 million and $163 million, with adjusted EBITDA expected to range from $9 million to $13 million. The company remains optimistic about its growth prospects, supported by strategic initiatives and strong product performance.</p>
<div class="lb-trans"><p>展望未来，Heron Therapeutics 重申了其财政年度的指导，预计净收入在 1.53 亿至 1.63 亿美元之间，调整后的 EBITDA 预计在 900 万至 1300 万美元之间。公司对其增长前景保持乐观，得益于战略举措和强劲的产品表现。</p>
</div><p>In conclusion, Heron Therapeutics’ earnings call reflects a company navigating through both opportunities and challenges. While strong growth in key product lines and successful financing are positive indicators, the decline in SUSTOL sales and gross margin decrease present areas for improvement. Overall, the company appears poised for growth, with strategic initiatives and forward-looking guidance providing a roadmap for future success.</p>
<div class="lb-trans"><p>总之，Heron Therapeutics 的财报电话会议反映出公司在机遇与挑战中前行。尽管关键产品线的强劲增长和成功融资是积极的指标，但 SUSTOL 销售下降和毛利率下降则是需要改进的领域。总体而言，公司似乎已做好增长的准备，战略举措和前瞻性指导为未来的成功提供了路线图。</p>
</div>

Heron Therapeutics 的财报电话会议：在挑战中实现增长